Lecanemab for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 6 registered trials.

Why this status

  1. 25 Mar 2019: Trial registered, NCT03887455
  2. 27 Mar 2019: Trial started, NCT03887455
  3. 25 Apr 2024: Trial registered, NCT06384573
  4. 10 Jun 2024: Trial started, NCT06384573
  5. 1 Jan 2026: Trial started, NCT07604896
  6. 22 May 2026: Trial registered, NCT07604896

The trials

NCT01767311: A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease

State
Completed
Phase
Phase 2
People
856 taking part
Started
20 Dec 2012
Primary completion
10 Dec 2024
Arms
Core Study: Lecanemab 2.5 mg/kg biweekly, Core Study: Lecanemab 5.0 mg/kg biweekly, Core Study: Lecanemab 10 mg/kg biweekly, Core Study: Lecanemab 5.0 mg/kg monthly, Core Study: Lecanemab 10 mg/kg monthly, Extension Phase: Lecanemab 10 mg/kg
Results
Posted on the registry
  1. 20 Dec 2012: Trial started
  2. 14 Jan 2013: Trial registered
  3. 10 Dec 2024: Trial completed
  4. 4 Mar 2026: Trial results posted

NCT02094729: A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

State
Completed
Phase
Phase 1
People
26 taking part
Started
Sep 2013
Primary completion
Mar 2015
Arms
BAN2401 2.5 mg/kg, BAN2401 5 mg/kg, BAN2401 10 mg/kg
Results
None posted
  1. 24 Mar 2014: Trial registered

NCT03887455: A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

State
Under way
Phase
Phase 3
People
1,906 taking part
Started
27 Mar 2019
Primary completion
31 Dec 2026
Arms
Core Study: Lecanemab 10 milligram per kilogram (mg/kg) biweekly, Extension Phase: Lecanemab 10 mg/kg biweekly, Extension Phase: Lecanemab Subcutaneous (SC) Injection Dose 1, Extension Phase: Lecanemab SC Injection Dose 2, Extension Phase: Lecanemab SC Injection Dose 3, Extension Phase: Lecanemab SC Injection Dose 4, Extension Phase: Lecanemab 10 mg/kg IV Infusion Once Every 4 Weeks (Q4W), Extension Phase B
Results
None posted
  1. 25 Mar 2019: Trial registered
  2. 27 Mar 2019: Trial started

NCT06384573: DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease

State
Under way
Phase
Phase 3
People
40 taking part
Started
10 Jun 2024
Primary completion
Jun 2030
Arms
lecanemab
Results
None posted
  1. 25 Apr 2024: Trial registered
  2. 10 Jun 2024: Trial started

NCT07604896: Evaluating the Efficacy and Safety of Lecanemab in Alzheimer's Disease Through Multi-omics Approachs

State
Under way
Phase
Phase 4
People
200 planned
Started
1 Jan 2026
Primary completion
31 Dec 2027
Arms
Lecanemab treatment group
Results
None posted
  1. 1 Jan 2026: Trial started
  2. 22 May 2026: Trial registered

NCT07688460: Evaluation System for Lecanemab Efficacy Using Gold Electrode ECL to Monitor Alzheimer's Biomarkers

State
Under way
Phase
Phase 4
People
100 planned
Started
10 Jul 2026
Primary completion
30 Mar 2029
Arms
Experimental: Lecanemab Treatment Group
Results
None posted
  1. 7 Jul 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as BAN2401 10 mg/kg, BAN2401 2.5 mg/kg, BAN2401 5 mg/kg, Lecanemab 10 mg/kg, Lecanemab 2.5 mg/kg, Lecanemab 5.0 mg/kg, Lecanemab IV, Lecanemab SC.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.